Clinical trials: Advanced Tumors
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies
This phase I trial studies the side effects and best dose of genetically modified T-cell therapy in treating patients with receptor tyrosine kinase-like orphan receptor 1 positive (ROR1+) chronic lymphocytic leukemia (CLL)…
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Triple-Negative Breast Carcinoma
- Trial name
- NCT02706392
- Testing
- Laboratory Biomarker Analysis, ROR1 CAR-specific Autologous T-Lymphocytes
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Fred Hutchinson Cancer Center
Gastric Cancer, Gastric Adenocarcinoma
A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer
A Phase 2, Multicenter, Open-Label Study of DKN-01 in Combination with Tislelizumab ± Chemotherapy as First-Line or Second-Line Therapy in Adult Patients with Inoperable, Locally Advanced or Metastatic Gastric or Gastroesophageal…
- Conditions
- Gastric Cancer, Gastric Adenocarcinoma, GastroEsophageal Cancer
- Trial name
- DisTinGuish (NCT04363801)
- Testing
- DKN-01 300mg, DKN-01 600mg, DKN-01 400mg
- Where
- 48 sites in United States, Germany and 1 more
- Volunteers
- 247 people
- Sponsor
- Leap Therapeutics, Inc.
Renal Cell Carcinoma, Graft-Versus-Host Disease
Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer
Background: Low-dose chemotherapy is easier for the body to tolerate than typical high-dose chemotherapy and involves a shorter period of complete immune suppression.
- Conditions
- Renal Cell Carcinoma, Graft-Versus-Host Disease, Engraftment Syndrome
- Trial name
- NCT00923845
- Testing
- Pentostatin, Sirolimus, Cyclophosphamide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Non-Small-Cell Lung
Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation
The purpose of the study was to learn whether the study drug (capmatinib) helps to control lung cancer better compared to a single agent chemotherapy (docetaxel) and whether it is safe when given to patients suffering from a…
- Trial name
- GeoMETry-III (NCT04427072)
- Testing
- Capmatinib, Docetaxel
- Where
- 43 sites in Belgium, Brazil and 16 more
- Volunteers
- 22 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Non-hematologic Malignancies
A Phase 1 Study of IXAZOMIB in Adult Patients With Advanced Nonhematologic Malignancies
This is an open-label, multicenter, phase 1, dose escalation study of IXAZOMIB. The primary purpose of this study is to determine the safety profile, establish the maximum tolerated dose, and inform the phase 2 dose of IXAZOMIB…
- Trial name
- NCT00830869
- Testing
- IXAZOMIB
- Where
- 7 sites in United States, Canada
- Volunteers
- 116 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma
Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer
This randomized phase III trial studies paclitaxel to see how well it works compared to polyglutamate paclitaxel or observation only in treating patients with stage III or stage IV ovarian epithelial, peritoneal cancer, or…
- Conditions
- Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma
- Trial name
- NCT00108745
- Testing
- Clinical Observation, Laboratory Biomarker Analysis, Paclitaxel
- Where
- 315 sites in United States
- Volunteers
- 1,157 people
- Sponsor
- GOG Foundation
Rash
Systemic and Topical Treatments for Rash Secondary to Erlotinib in Lung Cancer
The purpose of this trial is to determine if rash caused by erlotinib can be successfully treated and if so to determine the optimal treatment approach.
- Trial name
- LUTRAERL (NCT00473083)
- Testing
- Minocycline, Clindamycin 2% in hydrocortisone 1% lotion, Erlotinib
- Where
- 9 sites in Canada
- Volunteers
- 150 people
- Sponsor
- British Columbia Cancer Agency
Prostate Cancer Metastatic, Neuroendocrine Tumors
Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer
Eligible patients will be treated with the combination of lenvatinib and pembrolizumab. A cycle equals 21 days and therapy will continue until radiographic progression, intolerable toxicity, or patient/physician wishes to…
- Trial name
- PLANE-PC (NCT04848337)
- Testing
- Pembrolizumab, Lenvatinib
- Where
- 5 sites in United States
- Volunteers
- 45 people
- Sponsor
- University of Michigan Rogel Cancer Center
Head and Neck Cancer, Larynx
A Study of Chemo +/- Low-dose Radiation as Induction Therapy in SCCHN
The primary hypothesis of this study is that hyper-radiosensitivity (HRS) seen at extremely low doses of radiation can be exploited to enhance the effect of chemotherapy, and that this effect differs from the cellular effect of…
- Trial name
- NCT02126969
- Testing
- Low dose fractionated radiation - 80cGy with chemotherapy, Docetaxel and Carboplatin AUC 6
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Susanne Arnold
Solid Tumors
Japanese Phase 1 Trial of Sym004 in Solid Tumors
This trial is to assess the safety and tolerability of Sym004, administered weekly or biweekly as monotherapy in Japanese subjects with advanced solid tumors.This study consisted of two parts, a dose-escalation part ("Part-A")…
- Trial name
- NCT01955473
- Testing
- Sym004
- Where
- Germany
- Volunteers
- 51 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Advanced or Metastatic Solid Tumors, Previously Untreated Gastric Cancer
E7050 in Combination With Cisplatin and Capecitabine Versus Cisplatin and Capecitabine Alone in Patients With Advanced or Metastatic Solid Tumors and Previously Untreated Gastric Cancer
The purpose of this study is to determine the following: 1. Find the maximum tolerated dose of E7050 when given in combination with cisplatin and capecitabine in patients with advance or metastatic solid tumors, and 2) Whether…
- Trial name
- NCT01355302
- Testing
- E7050, cisplatin, capecitabine
- Where
- 19 sites in United States, Russia and 2 more
- Volunteers
- 7 people
- Sponsor
- Eisai Inc.
Esophageal Squamous Cell Carcinoma (ESCC)
A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
The purpose of this study is to evaluate the efficacy and safety of tislelizumab as first line treatment in combination with chemotherapy in participants with advanced unresectable/metastatic esophageal squamous cell carcinoma…
- Trial name
- NCT03783442
- Testing
- Cisplatin, Oxaliplatin, Fluorouracil (5-FU)
- Where
- 124 sites in United States, Australia and 14 more
- Volunteers
- 649 people
- Sponsor
- BeiGene
Melanoma, Solid Tumors
A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022)
This is a 5-part dose-finding and preliminary efficacy study of pembrolizumab (Pembro) + dabrafenib (D) + trametinib (T) for participants with advanced melanoma and solid tumors.
- Trial name
- NCT02130466
- Testing
- Pembrolizumab, Dabrafenib, Trametinib
- Volunteers
- 184 people
- Sponsor
- Merck Sharp & Dohme LLC
Breast Cancer
Compassionate Use of Eribulin for the Treatment of Advanced Breast Cancer Refractory to All Other Marketed Therapies
The purpose of this study is to provide eribulin to patients with advanced breast cancer who have no other treatment options and therapy is requested by an Investigator.
- Trial name
- NCT01142661
- Testing
- Eribulin Mesylate
- Where
- 5 sites in United States
- Volunteers
- 9 people
- Sponsor
- Eisai Inc.
Malignant Melanoma
IMCgp100-401 Rollover Study
IMCgp100-401 is a rollover study that is designed to provide continued access to IMCgp100 for eligible participants with advanced melanoma who have previously participated in an IMCgp100 study (parent study).
- Trial name
- NCT02889861
- Testing
- IMCgp100
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 3 people
- Sponsor
- Immunocore Ltd
Non Small Cell Lung Cancer
Dacomitinib + Pemetrexed for Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)
To identify a dose of dacomitinib in combination with pemetrexed that is safe and tolerated as determined by the incidence of DLTs (dose limiting toxicities).
- Trial name
- NCT01918761
- Testing
- Dacomitinib, Pemetrexed
- Where
- 2 sites in Austria
- Volunteers
- 5 people
- Sponsor
- Central European Cooperative Oncology Group
Adenocarcinoma of the Gastroesophageal Junction, Adenocarcinoma of the Stomach
Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction Cancer
This phase II trial is studying how well saracatinib works in treating patients with locally advanced or metastatic stomach or gastroesophageal junction cancer.
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Adenocarcinoma of the Stomach, Recurrent Gastric Cancer, Stage III Gastric Cancer
- Trial name
- NCT00607594
- Testing
- saracatinib
- Where
- 5 sites in United States, Canada
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Adenocarcinoma of the Gastroesophageal Junction, Esophageal Adenocarcinoma
Panitumumab, Combination Chemotherapy, & Radiation Therapy in Esophageal or Gastroesophageal Junction Cancer
This phase II trial is studying how well giving panitumumab, combination chemotherapy, and radiation therapy together before surgery works in treating patients with advanced esophageal or gastroesophageal (GE) junction cancer.
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Esophageal Adenocarcinoma, Stage IIA Esophageal Cancer, Stage IIB Esophageal Cancer
- Trial name
- NCT01307956
- Testing
- Fluorouracil, Laboratory Biomarker Analysis, Leucovorin Calcium
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Nebraska
Advanced Hepatocellular Carcinoma
Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC
The purpose of this study of capmatinib (INC280) and spartalizumab (PDR001) was to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of spartalizumab administered…
- Trial name
- NCT02795429
- Testing
- Spartalizumab, Capmatinib
- Where
- 17 sites in Canada, China and 6 more
- Volunteers
- 89 people
- Sponsor
- Novartis Pharmaceuticals
Non-Small Cell Lung Cancer
LDK378 in Adult Chinese Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
A single-Arm, open-label, multi-center, phase I/II study in which the pharmacokinetics, safety, tolerability and efficacy of LDK378 will be assessed in adult Chinese patients with locally advanced or metastatic NSCLC harboring a…
- Trial name
- NCT02040870
- Testing
- LDK378
- Where
- 15 sites in China
- Volunteers
- 103 people
- Sponsor
- Novartis Pharmaceuticals